Advancis Pharmaceutical (AVNNC) Reports a Q4 Loss, Issues Mixed Guidance for FY07
More News related to AVNC
- Advancis Pharmaceutical (AVNC) Concludes Pre-Phase III Meeting with FDA for Development of Keflex PULSYS Product Candidate
- StreetInsider.com Unusual 11 Mid-Day Movers 05/22/2007
- StreetInsider.com Pre-Open Movers 05/22
- Advancis Pharmaceutical (AVNC) Receives FDA Acceptance of Amoxicillin PULSYS NDA
- Advancis Pharmaceutical (AVNC) Announces $24 Million Private Placement of Common Equity
Advancis Pharmaceutical (Nasdaq: AVNC) reports a Q4 loss of $0.44 vs. consensus for a loss of $0.37. Revenues were $1.2 million vs. $2.38 million consensus.
Total revenue for 2007 is expected to be approximately $10 million to $14 million, resulting from Keflex product sales. Net loss for the year is expected to be between $36 million and $40 million, or approximately $0.99 to $1.10 per diluted common share. (FY07 revenue consensus is $23.11 million and EPS consensus is a loss of $1.02)
Related Categories
EarningsGuidance
Stocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
